A phase I study of doxercalciferol in recurrent pediatric solid tumors.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Doxercalciferol (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 11 Oct 2010 Planned end date changed from 1 Aug 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 10 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Feb 2008 Primary outcome added as reported by ClinicalTrials.gov.